Kardiologie

  Publications

2010 - today

 



257 Stefanini GG, Kalesan B, Pilgrim T, Raber L, Onuma Y, Silber S, Serruys PW, Meier B, Juni P, Windecker S.
Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents.
JACC Cardiovasc Interv; 5:301-310 (2012)
256 Van de Werf F, Ardissino D, Bueno H, Collet JP, Gershlick A, Kolh P, Kristensen SD, Silber S, Verheugt F, Wojakowski W.
Acute coronary syndromes: Considerations for improved acceptance and implementation of management guidelines.
Expert Rev Cardiovasc Ther; 10:489-503 (2012)
255 Neumann FJ, Cremer J, Falk V, Reifart N, Silber S, Thielmann M.
Comments on the joint guidelines on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
Der Kardiologe; 6: 94 – 104 (2012)
254 Abdel-Wahab M, Nienaber CA, Mostafa AE, Ferenc M, Silber S, Sabin G, Tebbe U, Akin I, Hochadel M, Senges J, Kuck KH, Richardt G.
Treatment of coronary bifurcation lesions with drug-eluting stents: Insights from the first phase of the prospective multicenter german drug-eluting stent registry.
J Interv Cardiol. (online first) (2012)
253 Beijk MA, Damman P, Klomp M, Woudstra P, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter AR.
Twelve-month clinical outcomes after coronary stenting with the genous bio-engineered R stent in patients with a bifurcation lesion: From the e-HEALING (healthy endothelial accelerated lining inhibits neointimal growth) registry.
Coronary Artery Disease; 23:201-207 (2012)
252 Leistner DM, Klotsche J, Palm S, Pieper L, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM.
Prognostic value of reported chest pain for cardiovascular risk stratification in primary care.
European Journal of Preventive Cardiology. (online first) (2012)
251 Willich SN, Müller-Riemenschneider F, McBride D, Silber S, Kuck KH, Nienaber CA, Schneider S, Senges J, Brüggenjürgen B.
Health economic evaluation of the use of drug-eluting stents : First results from the drug-eluting stent registry (des.De).
Herz (online first) 2012
250 Damman P, Klomp M, Silber S, Beijk MA, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter RJ.
Duration of dual antiplatelet therapy and outcomes after coronary stenting with the genous bio-engineered R stent in patients from the e-HEALING registry.
Catheter Cardiovasc Interv; 79:243-252 (2012)
249 Klomp M, Damman P, Beijk MA, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter RJ.
Applying the national institute for clinical excellence criteria to patients treated with the genous bio-engineered R stent: A sub-study of the e-HEALING (healthy endothelial accelerated lining inhibits neointimal growth) worldwide registry.
Heart and Vessels; 27:360-369 (2012)
248 Leistner DM, Klotsche J, Palm S, Pieper L, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM.
Resting heart rate as a tool for risk stratification in primary care: Does it provide incremental prognostic information?
European Journal of Preventive Cardiology; 19:275-284 (2012)
247 Leistner DM, Klotsche J, Pieper L, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM.
Circulating troponin as measured by a sensitive assay for cardiovascular risk assessment in primary prevention.
Clin Chem; 58:200-208 (2012)
246 Klomp M, Damman P, Beijk MA, Tan KH, Balian V, de Luca G, Tijssen JG, Silber S, de Winter RJ.
Differences in cardiovascular risk factors and clinical outcomes between western european and southeast asian patients treated with the genous bio-engineered R stent: An e-HEALING worldwide registry substudy.
Coronary Artery Disease; 23:271-277 (2012)
245 Silber S, Tan HC, Iniguez A, Scacciatella P, Smith D, Kutryk M, Brugaletta S
Relative clinical contraindications to the use of drug-eluting stents: what are the alternatives?
Cardiology International, 45 - 48 (2012)
244 National Guidelines for Diagosis and Treatment of Chronic Coronary Artery Disease
www.versorgungsleitlinien.de

www.versorgungsleitlinien.de
243 Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, Marco J, Gitt AK
Impact of diabetes mellitus status on coronary pathoanatomy and interventional treatment: Insights from the EURO HEART survey PCI registry.
Catheter Cardiovasc Interv; 78:702-709 (2011)
242 Bauer T, Nienaber CA, Akin I, Kuck KH, Hochadel M, Senges J, Fetsch T, Tebbe U, Willich SN, Stumpf J, Sabin GV, Silber S, Richardt G, Zahn R.
Comparison between on-label versus off-label use of drug-eluting coronary stents in clinical practice: Results from the german des.De-registry.
Clin Res Cardiol; 100:701-709 (2011)
241 Damman P, Iniguez A, Klomp M, Beijk M, Woudstra P, Silber S, Ribeiro EE, Suryapranata H, Sim KH, Tijssen JG, de Winter RJ.
Coronary stenting with the genous bio-engineered R stent in elderly patients.
Circ J; 75:2590-2597 (2011)
240 Damman P, Klomp M, Beijk MA, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter RJ.
Twelve-month outcomes after coronary stenting with the genous bio-engineered R stent in diabetic patients from the e-HEALING registry.
J Interv Cardiol; 24:285-294 (2011)
239 de Mulder M, Gitt A, van Domburg R, Hochadel M, Seabra-Gomes R, Serruys PW, Silber S, Weidinger F, Wijns W, Zeymer U, Hamm C, Boersma E.
Euroheart score for the evaluation of in-hospital mortality in patients undergoing percutaneous coronary intervention.
Eur Heart J; 32:1398-1408 (2011)
238 den Dekker WK, Houtgraaf JH, Onuma Y, Benit E, de Winter RJ, Wijns W, Grisold M, Verheye S, Silber S, Teiger E, Rowland SM, Ligtenberg E, Hill J, Wiemer M, den Heijer P, Rensing BJ, Channon KM, Serruys PW, Duckers HJ.
Final results of the HEALING-IIb trial to evaluate a bio-engineered cd34 antibody coated stent (Genous stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients.
Atherosclerosis; 219:245-252 (2011)
237 Garg S, Serruys PW, Silber S, Wykrzykowska J, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Van Remortel E, Ronden J, Windecker S.
The prognostic utility of the syntax score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the resolute all comers trial.
JACC Cardiovasc Interv; 4:432-441 (2011)
236 Gomez-Lara J, Heo JH, Brugaletta S, Garg S, Garcia-Garcia HM, van Geuns RJ, Silber S, Windecker S, Serruys PW.
Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents.
Am Heart J; 162:1069-1079 e1062 (2011)
235 Gutierrez-Chico JL, van Geuns RJ, Regar E, van der Giessen WJ, Kelbaek H, Saunamaki K, Escaned J, Gonzalo N, di Mario C, Borgia F, Nuesch E, Garcia-Garcia HM, Silber S, Windecker S, Serruys PW.
Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. A fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: An optical coherence tomography substudy from the resolute all comers trial.
Eur Heart J; 32:2454-2463 (2011)
234 Schneider HJ, Klotsche J, Silber S, Stalla GK, Wittchen HU.
Measuring abdominal obesity: Effects of height on distribution of cardiometabolic risk factors risk using waist circumference and waist-to-height ratio.
Diabetes Care; 34:e7 (2011)
233 Silber S, Damman P, Klomp M, Beijk MA, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Hian Sim K, Tijssen JG, de Winter RJ.
Clinical results after coronary stenting with the genous bio-engineered R stent: 12-month outcomes of the e-HEALING (healthy endothelial accelerated lining inhibits neointimal growth) worldwide registry.
EuroIntervention; 6:819-825 (2011)
232 Silber S, Gutierrez-Chico JL, Behrens S, Witzenbichler B, Wiemer M, Hoffmann S, Slagboom T, Harald D, Suryapranata H, Nienaber C, Chevalier B, Serruys PW.
Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: The EUROSTAR-II randomised clinical trial.
EuroIntervention; 7:64-73 (2011)
231 Silber S, Helms TM, Garlichs C, Arntz HR, Weil J, Ince H, Klingenheben T, Hoffmann S, Boudriot E, Steiger H, Zugck C.
Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: What is state-of-the-art?
Dtsch Med Wochenschr; 136:782-785 (2011)
230 Silber S, Windecker S, Vranckx P, Serruys PW
Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the resolute all comers trial.
Lancet; 377:1241-1247 (2011)
229 Stefanini GG, Serruys PW, Silber S, Khattab AA, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, Di Mario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli AL, Gobbens P, Windecker S.
The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the resolute all comers trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention).
J Am Coll Cardiol; 57:2221-2232 (2011)
228 Stella PR, Belkacemi A, Waksman R, Stahnke S, Torguson R, von Strandmann RP, Agostoni P, Sangiorgi G, Silber S
The VALENTINES trial: Results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation dior paclitaxel drug-eluting balloon for in-stent restenosis treatment.
227 Bauer T, Mollmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, Marco J, Gitt AK.
Predictors of hospital mortality in the elderly undergoing percutaneous coronary intervention for acute coronary syndromes and stable angina.
Int J Cardiol; 151:164-169 (2011)
226 Silber S
Immediate and Long-Term Therapy of Patients with Acute Coronary Syndromes with Thienopyridines.
Current Status According to the Latest European Society of Cardiology (ESC) Guidelines
RMMJ; 2: e0056 (2011)
225 Silber S, Van de Werf F. and Members of the Task Force
Pocket Guidelines for the Diagnosis and Treatment of Patients with Acute Coronary Syndrome and Persistent ST-Segment Elevation (STEMI)
Der Kardiologe; 4:93-106 (2010)
224 Silber S, Borggrefe M, Hasenfuß G, Falk V, Kastrati A, Weis M, Hamm CW.
Commentary on the Guidelines of the European Society of Cardiology (ESC) regarding the Diagnosis and Treatment of Patients with ST-Segment Elevation Myocardial Infarction (STEMI)
Der Kardiologe; 4:84-92 (2010)
223 Bauer T, Mollmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, Marco J, Gitt AK.
Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: Impact of clinical status and procedural characteristics.
Clin Res Cardiol; 99:375-383 (2010)
222 Mahabadi AA, Achenbach S, Burgstahler C, Dill T, Fischbach R, Knez A, Moshage W, Richartz BM, Ropers D, Schröder S, Silber S, Möhlenkamp S.
Safety, efficacy, and indications of beta-adrenergic receptor blockade to reduce heart rate prior to coronary ct angiography.
Radiology; 257:614-623 (2010)
221 Schneider HJ, Friedrich N, Klotsche J, Pieper L, Nauck M, John U, Dorr M, Felix S, Lehnert H, Pittrow D, Silber S, Volzke H, Stalla GK, Wallaschofski H, Wittchen HU.
The predictive value of different measures of obesity for incident cardiovascular events and mortality.
J Clin Endocrinol Metab; 95:1777-1785 (2010)
220 Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S.
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
N Engl J Med; 363:136-146 (2010)
219 Silber S
Evidence-based management of ST-segment elevation myocardial infarction (STEMI). Latest Guidelines of the European Society of Cardiology (ESC).
Herz; 35:558-564 (2010)
218 Vranckx P, Cutlip DE, Mehran R, Kint PP, Silber S, Windecker S, Serruys PW.
Myocardial infarction adjudication in contemporary all-comer stent trials: Balancing sensitivity and specificity. Addendum to the historical mi definitions used in stent studies.
217 Hoffmeister HH, Bode C, Darius H, Huber K, Rybak K, Silber S
Bridging of Antithrombotic Therapy in Patients with Cardiovascular Disease. Position Paper of the German Society of Cardiology (DGK)
Der Kardiologe; 4: 365-374 (2010)
216 Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D.
Guidelines on Myocardial Revascularization of the European Society of Cardiology (ESC)
Eur Heart J; 31:2501-2555 (2010)